Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity
NCT06299891
This study is recruiting at 2 US sites in 2 states, according to its ClinicalTrials.gov record last updated .
Summary
Hypothalamic obesity (HO) refers to the substantial weight gain that often complicates hypothalamic brain tumors. Children with this treatment-recalcitrant form of obesity have excess rates of metabolic sequelae compared to otherwise healthy children with similar obesity, and later experience excess mortality related to cardiometabolic disease. In this pilot trial, our objective is to gather key preliminary data about phentermine/topiramate (Ph/T) that is FDA-approved for "common" obesity but has never been tested in HO.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Hypothalamic Obesity
- Hypothalamic Tumor
- Craniopharyngioma
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 6 to 28 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Seattle Children's Hospital
- Last updated on ClinicalTrials.gov
- July 28, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Pennsylvania · 1
- The Children's Hospital of Philadelphia · Philadelphia, PA
Washington · 1
- Seattle Children's · Seattle, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.